natgillin/translations-raw huggingface dataset:
• if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer) - a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body) - a recent serious injury - a recent surgery (including dental) - a planned surgery (including dental) in the next seven days 
Ako postoji opasnost od krvarenja poput - medicinskih stanja kod kojih postoji opasnost od unutrašnjeg krvarenja (kao što je želučani čir), - poremećaja krvi zbog čega ste skloni unutrašnjim krvarenjima (krvarenje u tkivima, organima ili zglobovima), - nedavne teške ozljede, - nedavnog kirurškog zahvata (uključujući stomatološke zahvate), - planiranog kirurškog zahvata (uključujući stomatološke zahvate) u sljedećih sedam dana.
This benefit was consistent across age, gender and with or without fibrinolytics, and was observed as early as 24 hours. 
Taj učinak je bio dosljedan u odnosu na dob, spol i primjenu fibrinolitika i opažen je unutar 24 sata.
A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non- fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins. 
Fibrinolitike je primalo 99,7% bolesnika (fibrin-specifični: 68,7%, fibrin-nespecifični: 31,1%), 89,5% heparin, 78,7% beta blokatore, 54,7% ACE inhibitore i 63% statine.
See leaflet for further information. 
Vidjeti Uputu o lijeku za dodatne informacije.
The CYP2C19*2 and CYP2C19*3 alleles account for 85% of reduced function alleles in whites and 99% in Asians. 
CYP2C19*2 i CYP2C19*3 aleli čine većinu alela sa smanjenom funkcijom u slabih metabolizatora u bijelaca (85%) i Azijata (99%).
• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
UVJETI ILI OGRANIČENJA VEZANI UZ SIGURNU I UČINKOVITU PRIMJENU LIJEKA
3542 DR Utrecht The Netherlands 
Computerweg 10 3542 DR Utrecht Nizozemska
Bleeding and haematological disorders 
Krvarenje i hematološki poremećaji
Clopidogrel Teva Generics B.V. belongs to a group of medicines called antiplatelet medicinal products. 
Klopidogrel Teva Generics B.V. sadrži klopidogrel i pripada skupini lijekova koji se nazivaju antitrombocitni lijekovi.
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR=43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR=18.2%; CI: 6.5%, 28.3%). 
Primjena klopidogrela u studiji CURE bila je povezana sa smanjenjem potrebe za trombolitičkom terapijom (RRR = 43,3%; CI: 24,3%, 57,5%) i inhibitorima GPIIb/IIIa (RRR = 18,2%; CI: 6,5%,
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively. 
Novi su kardiovaskularni događaji (primarni ishod) spriječeni, sa smanjenjem relativnoga rizika od 22% (CI: 8,6, 33,4), 32% (CI: 12,8, 46,4), 4% (CI: -26,9, 26,7), 6% (CI: -33,5, 34,3) i 14% (CI: -31,6, 44,2) tijekom studijskih razdoblja od 0 do 1 mjesec, 1 do 3 mjeseca, 3 do 6 mjeseci, 6 do 9 mjeseci, odnosno 9 do 12 mjeseci.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Teva Generics B.V. (4 tablets of 75 mg) once at the start of treatment. 
Ako ste imali jake bolove u prsištu (nestabilna angina ili srčani udar), liječnik Vam u početku liječenja može jednokratno dati 300 mg lijeka Klopidogrel Teva Generics B.V (4 tablete of 75 mg).
Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites. 
Apsorpcija iznosi najmanje 50%, na temelju izlučivanja metabolita klopidogrela putem mokraće.
Heparin: in a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation. 
Heparin: u jednoj kliničkoj studiji provedenoj na zdravim ispitanicima, primjena klopidogrela nije iziskivala promjenu doze heparina, niti je mijenjala učinak heparina na koagulaciju.
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450. 
In vitro i in vivo, klopidogrel se metabolizira kroz dva glavna metabolička puta: jednim posredovanim esterazom, koji dovodi do hidrolize u neaktivni derivat karboksilne kiseline (koji čini 85% cirkulirajućih metabolita) i drugim posredovanim višestrukim enzimima skupine citokroma P450.
The safety and efficacy of clopidogrel have been evaluated in 4 double-blind studies involving over 80,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY and COMMIT studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy. 
Sigurnost primjene i djelotvornost klopidogrela procijenjena je u 5 dvostrukoslijepih studija koje su uključivale više od 88 000 bolesnika: studija CAPRIE, u kojoj su uspoređivani klopidogrel i ASK, te studije CURE, CLARITY, COMMIT i ACTIVE-A u kojima je uspoređivano djelovanje klopidogrela u odnosu na placebo, a obje su terapije davane u kombinaciji s ASK i drugom standardnom terapijom.
This benefit was consistent across all prespecified subgroups including patients' age and gender, infarct location, and type of fibrinolytic or heparin used. 
Ovaj učinak bio je dosljedno prisutan u svim prethodno određenim podskupinama koje su uključivale dob i spol bolesnika, lokaciju infarkta i tip primijenjenog fibrinolitika ili heparina.
Animal studies have shown excretion of clopidogrel in breast milk. 
Ispitivanja na životinjama pokazala su da se klopidogrel izlučuje u mlijeko.
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4). 
Inhibitori glikoproteina IIb/IIIa: klopidogrel se s oprezom mora davati bolesnicima koji istodobno primaju inhibitore glikoproteina IIb/IIIa (vidjeti dio 4.4.).
Very rare 
Manje često
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. 
- Akutni infarkt miokarda s elevacijom ST-segmenta, u kombinaciji s ASK u medikamentozno liječenih bolesnika pogodnih za liječenje trombolitičkom terapijom.
For patients over 75 years of age clopidogrel should be initiated without a loading dose. 
U bolesnika starijih od 75 godina liječenje klopidogrelom ne treba započinjati udarnom dozom.
You should also be given acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting) by your doctor. 
Liječnik će Vam propisati i acetilsalicilatnu kiselinu (tvar koju sadrže mnogi lijekovi za ublažavanje boli i snižavanje povišene temperature, kao i oni za sprječavanje stvaranja krvnih ugrušaka).
You have been prescribed Clopidogrel Teva Generics B.V. to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack). 
Vam je propisan za sprječavanje stvaranja krvnih ugrušaka i smanjivanje opasnosti od ovih ozbiljnih događaja jer: - imate otvrdnuće arterija (koje se još zove ateroskleroza) - ste već imali srčani udar, moždani udar ili imate stanje koje se zove bolest perifernih arterija, ili - ste imali teški oblik boli u prsištu, poznat pod nazivom „nestabilna angina“ ili „infarkt miokarda“ (srčani udar).
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN 
POSEBNO UPOZORENJE O ČUVANJU LIJEKA IZVAN POGLEDA
At very high doses, a poor gastric tolerability (gastritis, gastric erosions and/or vomiting) of clopidogrel was also reported in rat and baboon. 
Pri vrlo visokim dozama, također je zabilježena slaba želučana podnošljivost klopidogrela (gastritis, erozije želuca i/ili povraćanje) u štakora i babuna.
In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT. 
U bolesnika s akutnim infarktom miokarda sa ST elevacijom (STEMI), sigurnost primjene i djelotvornost klopidogrela procijenjena je u 2 randomizirane, dvostrukoslijepe, placebom kontrolirane studije, CLARITY i COMMIT.
Clopidogrel has no or negligible influence on the ability to drive and use machines. 
Klopidogrel ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4). 
Tako se, nakon 3 mjeseca, zabilježena korist liječenja kombinacijom klopidogrela + ASK nije dalje povećavala, dok je opasnost od krvarenja i nadalje postojala (vidjeti dio 4.4.).
This medicinal product contains hydrogenated castor oil which may cause stomach upset and diarrhoea. 
Ovaj lijek sadrži hidrogenirano ricinusovo ulje koje može uzrokovati probavne tegobe i proljev.
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD). 
Studija CAPRIE uključivala je 19 185 bolesnika s aterotrombozom koja se manifestirala kao nedavni infarkt miokarda (<35 dana), nedavni ishemijski moždani udar (između 7 dana i 6 mjeseci) ili utvrđena bolest perifernih arterija (BPA).
Within each system organ class, adverse drug reactions are presented in order of decreasing seriousness. 
Unutar svakog organskog sustava nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects') 
Također, odmah obavijestite svog liječnika ako se pojavi medicinsko stanje (koje se naziva "trombotična trombocitopenična purpura" ili "TTP") sa simptomima koji uključuju vrućicu i potkožne modrice koje se mogu pojaviti kao crvene točkice, sa ili bez neobjašnjivog teškog umora, zbunjenosti i žute boje kože ili očiju (žutica) (vidjeti dio 4. "Moguće nuspojave").
Overdose following clopidogrel administration may lead to prolonged bleeding time and subsequent bleeding complications. 
Predoziranje klopidogrelom može produljiti vrijeme krvarenja i naknadno dovesti do komplikacija s krvarenjem.
The CLARITY trial included 3,491 patients presenting within 12 hours of the onset of a ST elevation MI and planned for thrombolytic therapy. 
Ispitivanje CLARITY uključivalo je 3491 bolesnika, koji su unutar 12 sati imali infarkt miokarda s elevacijom ST-spojnice i planirala im se trombolitička terapija.
These occurred at doses representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day and were a consequence of an effect on hepatic metabolising enzymes. 
One su se javljale pri dozama koje su bile barem 25 puta veće od izloženosti u bolesnika koji su primali kliničku dozu od 75 mg klopidogrela na dan i bile su posljedice učinka na jetrene metaboličke enzime.
Other alleles associated with reduced metabolism include CYP2C19*4, *5, *6, *7, and *8, but these are less frequent in the general population. 
Ostali aleli povezani s odsutnim ili smanjenim metabolizmom uključuju CYP2C19*4, *5, *6, *7 i *8, ali oni su manje zastupljeni.
Due to the irreversible binding, platelets exposed are affected for the remainder of their lifespan (approximately 7-10 days) and recovery of normal platelet function occurs at a rate consistent with platelet turnover. 
Zbog ireverzibilnog vezanja, izloženi trombociti zahvaćeni su ovim učinkom do kraja svog životnog vijeka (oko 7-10 dana), a normalna funkcija trombocita obnavlja se brzinom koja odgovara brzini stvaranja novih trombocita.
What Clopidogrel Teva Generics B.V. is and what it is used for Before you take Clopidogrel Teva Generics B.V. How to take Clopidogrel Teva Generics B.V. 
Što je Klopidogrel Teva Generics B.V. i za što se koristi Što morate znati prije nego što počnete uzmati Klopidogrel Teva Generics B.V.
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. 
Aktivni metabolit klopidogrela selektivno inhibira vezanje adenozin difosfata (ADP) za njegov receptor P2Y12 na trombocitima te posljedično i ADP-om posredovano aktiviranje kompleksa GPIIb/IIIa, inhibirajući na taj način agregaciju trombocita.
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the coadministration of phenobarbital, or oestrogen. 
Nadalje, na farmakodinamičku aktivnost klopidogrela nije značajno utjecala istodobna primjena fenobarbitala ili estrogena.
- This medicine has been prescribed for you. 
- Ovaj je lijek propisan samoVama.
After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects. 
Nakon ponovljenih dnevnih doza klopidogrela od 75 mg tijekom deset dana, u bolesnika s teško oštećenom funkcijom jetre inhibicija ADP-om inducirane agregacije trombocita bila je slična u usporedbi sa zdravim ispitanicima.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Teva Generics B.V.. 
Ako ste trudni ili sumnjate na trudnoću, obavijestite svog liječnika ili ljekarnika prije nego što uzmete Klopidogrel Teva Generics B.V.
A pharmacodynamic interaction between clopidogrel and acetylsalicylic acid is possible, leading to increased risk of bleeding. 
Farmakodinamička interakcija između klopidogrela i acetilsalicilatne kiseline moguća je i ona može povećati rizik od krvarenja.
Elimination Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing. 
C u ljudi, približno 50% doze izlučilo se u mokraću, a približno 46% u stolicu u intervalu od 120 sati nakon doziranja.
LIST OF EXCIPIENTS It also contains hydrogenated castor oil. 
POPIS POMOĆNIH TVARI Također sadrži: hidrogenirano ricinusovo ulje.
The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST depression or left bundle-branch block). 
COMMIT ispitivanje faktorskog dizajna 2x2, uključivalo je 45 852 bolesnika koji su unutar posljednja 24 sata pretrpjeli simptome suspektne na infarkt miokarda, s pratećim abnormalnostima EKG-a (primjerice ST elevacija, ST depresija ili blok lijeve grane snopa).
A pharmacodynamic interaction between clopidogrel and heparin is possible, leading to increased risk of bleeding. 
Farmakodinamička interakcija između klopidogrela i heparina je moguća i može povećati rizik od krvarenja.
The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8). 
Incidencija klinički značajnog krvarenja bila je slična onoj zamijećenoj pri istodobnoj primjeni trombolitika i heparina s ASK (vidjeti dio 4.8.).
Clopidogrel Teva Generics B.V. is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Klopidogrel Teva Generics B.V. uzimaju odrasli za sprječavanje stvaranja krvnih ugrušaka (tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
In a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported. 
U manjem su broju slučajeva zabilježena i krvarenja u oku, glavi, plućima ili zglobovima.
Esomeprazole is expected to give a similar interaction with clopidogrel. 
Očekuju se i slične interakcije između esomeprazola i klopidogrela.
Medicinal products that inhibit CYP2C19 include omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol. 
Lijekovi koji inhibiraju CYP2C19 uključuju omeprazol i esomeprazol, fluvoksamin, fluoksetin, moklobemid, vorikonazol, flukonazol, tiklopidin, ciprofloksacin, cimetidin, karbamazepin, okskarbazepin i kloramfenikol.
Film coating: 
Film-ovojnica:
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel treated group and 363 (5.8%) in the placebo treated group]. 
Na taj učinak najviše je utjecalo statistički značajno smanjenje incidencije infarkta miokarda [287 (4,6%) u skupini koja je primala klopidogrel i 363 (5,8%) u skupini koja je primala placebo].
• Your doctor may order blood tests 
Liječnik će možda odrediti da Vam se naprave pretrage krvi.
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2-2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing. 
Srednje vršne razine nepromijenjenog klopidogrela u plazmi (oko 2,2 - 2,5 ng/ml nakon jednokratne oralne doze od 75 mg) postižu se otprilike 45 minuta nakon uzimanja lijeka.
Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction. 
Trombolitici: sigurnost istodobne primjene klopidogrela, fibrinskih ili afibrinskih specifičnih trombolitika i heparina procjenjivana je u bolesnika s akutnim infarktom miokarda.
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles correspond to reduced metabolism. 
CYP2C19*1 alel odgovara potpuno funkcionalnom metabolizmu, dok su CYP2C19*2 i CYP2C19*3 aleli nefunkcionalni.
Pharmacogenetics 
Farmakogenetika
Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race. 
Sveukupno su, u studiji CAPRIE, podaci za klopidogrel u dozi od 75 mg/dan bili slični podacima za ASK u dozi od 325 mg/dan, bez obzira na dob, spol ili rasu.
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY and COMMIT studies are discussed below. 
Klinički značajne nuspojave opažene u studijama CAPRIE, CURE, CLARITY i COMMIT i ACTIVE-A opisane su u daljnjem tekstu.
The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel. 
Farmakokinetika digoksina ili teofilina nije se mijenjala pri istodobnoj primjeni klopidogrela.
Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation. 
Acetilsalicilna kiselina (ASK): ASK nije promijenila klopidogrelom posredovanu inhibiciju agregacije trombocita koju inducira ADP, ali je klopidogrel potencirao učinak ASK na agregaciju trombocita posredovanu kolagenom.
Clopidogrel significantly reduced the incidence of new ischaemic events (combined end point of myocardial infarction, ischaemic stroke and vascular death) when compared to ASA. 
U usporedbi s ASK, klopidogrel je značajno smanjio incidenciju novih ishemijskih događaja (kombinirani ishod infarkta miokarda, ishemijskog moždanog udara i vaskularne smrti).
Luxembourg/Luxemburg Teva Pharma Belgium S.A. Tél/Tel: +32 3 820 73 73 
Teva Pharma Belgium N.V./S.A./AG Tél/Tel: +32 3 820 73 73
Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype. 
Farmakokinetika i antitrombocitni učinak aktivnog metabolita klopidogrela, mjereni u ex vivo testovima agregacije trombocita, razlikuju se ovisno o genotipu CYP2C19.
After a single oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours. 
Nakon jednokratne oralne primjene klopidogrela u dozi od 75 mg, poluvijek klopidogrela iznosio je otprilike 6 sati.
Pink, round and slightly convex film-coated tablets. 
Ružičaste, okrugle i blago ispupčene, filmom obložene tablete.
The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors). 
Zabilježena korist liječenja klopidogrelom bila je neovisna o drugoj akutnoj ili dugotrajnoj kardiovaskularnoj terapiji (kao što su: heparin/heparini male molekularne težine, antagonisti GPIIb/IIIa, lijekovi za snižavanje kolesterola, beta blokatori i ACE inhibitori).
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography. 
Primarni ishod bio je pojava okludirane koronarne arterije koja je najvjerovatnije dovela do infarkta miokarda na angiogramu učinjenom prije otpusta, smrt ili ponovljeni infarkt miokarda prije koronarne angiografije.
No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with atenolol, nifedipine, or both atenolol and nifedipine. 
Nisu primijećene klinički značajne farmakodinamičke interakcije pri istodobnoj primjeni klopidogrela i atenolola, odnosno nifedipina, ili klopidogrela i ta dva lijeka zajedno.
Heparins were administered in more than 90% of the patients and the relative rate of bleeding between clopidogrel and placebo was not significantly affected by the concomitant heparin therapy. 
Heparin je primalo više od 90% bolesnika, a na relativni stupanj krvarenja u skupini koja je primala klopidogrel i onoj koja je primala placebo nije značajno utjecalo istodobno liječenje heparinom.
Adverse reactions that occurred either during clinical studies or that were spontaneously reported are presented in the table below. 
Nuspojave prikupljene u kliničkim studijama kao i nuspojave prijavljene spontano, nabrojene su u tablici.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p<0.001), mainly related to a reduction in occluded infarct-related arteries. 
Petnaest posto (15,0%) bolesnika u skupini s klopidogrelom i 21,7% u skupini s placebom dostigli su primarni ishod, što predstavlja apsolutno smanjenje od 6,7% i smanjenje izgleda (engl. odds reduction) od 36% u korist klopidogrela (95% CI: 24, 47%; p<0,001), većinom povezano sa smanjenjem okluzije arterija povezanih s infarktom.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed clopidogrel in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. 
Ako ste imali jaku bol u prsištu (nestabilna angina ili srčani udar), liječnik Vam može propisati Klopidogrel Teva Generics B.V u kombinaciji s acetilsalicilatnom kiselinom, tvari prisutnom u mnogim lijekovima za ublažavanje boli i snižavanje temperature.